{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:15:17Z","timestamp":1779282917526,"version":"3.51.4"},"reference-count":104,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bulcan.2025.04.014","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T19:54:42Z","timestamp":1754942082000},"page":"S111-S130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Anticipation des probl\u00e8mes pharmacoth\u00e9rapeutiques en amont de l\u2019allogreffe (SFGM-TC)"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-440X","authenticated-orcid":false,"given":"Nicolas","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Jouvance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Roch-Torreilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0525","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41409-021-01502-8","article-title":"Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT","volume":"57","author":"Penack","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0530","unstructured":"Agence de la biom\u00e9decine. Le rapport m\u00e9dical et scientifique du pr\u00e9l\u00e8vement et de la greffe en France. Rapport annuel 2023. https:\/\/rams.agence-biomedecine.fr\/activite-nationale-de-greffe-de-csh-0 (acc\u00e8s le 20\/09\/2024)."},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.014_bib0535","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.jtct.2021.01.001","article-title":"Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults","volume":"27","author":"Sugidono","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.bulcan.2025.04.014_bib0540","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.bbmt.2020.08.031","article-title":"Use of potentially inappropriate medications in older allogeneic hematopoietic cell transplantation recipients","volume":"26","author":"Bhargava","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.014_bib0545","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-019-03791-9","article-title":"Potential drug-drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay","volume":"83","author":"Sanchez","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0550","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1078155218782372","article-title":"Clinical pharmacists\u2019 contributions to hematopoietic stem cell transplantation: a systematic review","volume":"25","author":"Barboza-Zanetti","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.014_bib0555","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/1078155220943964","article-title":"Clinical pharmacy in onco-hematology and bone marrow transplant: a valuable contribution to improving patient safety","volume":"27","author":"Visacri","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0560","doi-asserted-by":"crossref","first-page":"683","DOI":"10.18549\/PharmPract.2016.02.683","article-title":"Immunosuppressive serum levels in allogeneic hematopoietic stem cell transplantation: pharmaceutical care contribution","volume":"14","author":"Corr\u00eaa","year":"2016","journal-title":"Pharm Pract (Granada)"},{"issue":"12","key":"10.1016\/j.bulcan.2025.04.014_bib0565","first-page":"3441","article-title":"Impact of clinical pharmacist-based parenteral nutrition service for bone marrow transplantation patients: a randomized clinical trial","volume":"21","author":"Mousavi","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1S","key":"10.1016\/j.bulcan.2025.04.014_bib0570","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.bulcan.2018.07.020","article-title":"[Clinical pharmacy in a bone marrow and cellular therapy transplantation ward-which methods to put in place: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]","volume":"106","author":"Forcade","year":"2019","journal-title":"Bull Cancer"},{"issue":"2S","key":"10.1016\/j.bulcan.2025.04.014_bib0575","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.bulcan.2022.02.004","article-title":"Drug-drug interactions and physicochemical incompatibilities during acute phase after allo-SCT: guidelines from the SFGM-TC","volume":"110","author":"Bruno","year":"2023","journal-title":"Bull Cancer"},{"issue":"11S","key":"10.1016\/j.bulcan.2025.04.014_bib0580","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.014_bib0585","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1523-1755.2005.00301.x","article-title":"Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant","volume":"67","author":"Parikh","year":"2005","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.bulcan.2025.04.014_bib0590","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/bmt.2015.188","article-title":"Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients","volume":"50","author":"Shingai","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0695","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. At\u00e9nolol\/chlortalidone (TENORETIC\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=62980497 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0700","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Hydrochlorothiazide (ESIDREX\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66153192 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0705","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Indapamide (FLUDEX\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=69784540 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0710","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Furos\u00e9mide (LASILIX\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65606743 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0715","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Amiloride (MODAMIDE\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=63371015 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0720","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Spironolactone (ALDACTONE\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=64565845 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0725","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Ac\u00e9butolol (SECTRAL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66931921 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0730","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Amlodipine (AMLOR\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=61939921 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0735","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Diltiazem (TILDIEM\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=63692245 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0740","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. V\u00e9rapamil (ISOPTINE\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66814925 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0745","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. P\u00e9rindopril (COVERSYL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=68391071 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0750","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Valsartan (TAREG\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=67813947 (acc\u00e8s le 20\/09\/2024)."},{"issue":"10296","key":"10.1016\/j.bulcan.2025.04.014_bib0595","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2\u00a0inhibitors and GLP-1\u00a0receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0600","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12944-022-01665-3","article-title":"Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Lu","year":"2022","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0605","doi-asserted-by":"crossref","first-page":"e70165","DOI":"10.1002\/iid3.70165","article-title":"Fluvastatin promotes treg cell production in allogeneic immune reaction and suppresses inflammatory response","volume":"13","author":"Chen","year":"2025","journal-title":"Immun Inflamm Dis"},{"issue":"11","key":"10.1016\/j.bulcan.2025.04.014_bib0610","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1345\/aph.19039","article-title":"Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine","volume":"33","author":"Maltz","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0615","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1060028019871891","article-title":"Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions","volume":"54","author":"Migliozzi","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"3\u00a0Suppl","key":"10.1016\/j.bulcan.2025.04.014_bib0625","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association's Safety Task Force. A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.1016\/j.bulcan.2025.04.014_bib0630","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a Scientific Statement From the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib0635","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ph17030294","article-title":"A drug safety briefing (II) in transplantation from real-world individual pharmacotherapy management to prevent patient and graft from polypharmacy risks at the very earliest stage","volume":"17","author":"Wolf","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.bulcan.2025.04.014_bib0640","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjcard.2004.06.033","article-title":"Risk of adverse events with fibrates","volume":"94","author":"Alsheikh-Ali","year":"2004","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib0755","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/0091270005284852","article-title":"Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients","volume":"46","author":"Bergman","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.bulcan.2025.04.014_bib0760","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/jcm11144080","article-title":"Dyslipidemia in transplant patients: which therapy?","volume":"11","author":"Iannuzzo","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0645","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11239-023-02902-x","article-title":"Characterization of direct oral anticoagulants use in adult hematopoietic stem cell transplant recipients","volume":"57","author":"Yang","year":"2024","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"10.1016\/j.bulcan.2025.04.014_bib0620","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2025.04.014_bib0650","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021\u00a0European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.bulcan.2025.04.014_bib0655","doi-asserted-by":"crossref","first-page":"e007956","DOI":"10.1161\/CIRCEP.121.007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0660","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40262-021-01051-9","article-title":"Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as a microdosed cocktail","volume":"61","author":"Rohr","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.014_bib0665","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.amjmed.2021.11.008","article-title":"Bleeding risk following systemic fluconazole or topical azoles in patients with atrial fibrillation on apixaban, rivaroxaban, or dabigatran","volume":"135","author":"Holt","year":"2022","journal-title":"Am J Med"},{"issue":"13","key":"10.1016\/j.bulcan.2025.04.014_bib0670","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0765","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Acide ac\u00e9tylsalicylique (KARDEGIC\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=64755969 (acc\u00e8s le 20\/09\/2024)."},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.014_bib0770","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19\u00a0genotype and clopidogrel therapy: 2022\u00a0update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0775","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12872-016-0453-6","article-title":"Is the concomitant use of clopidogrel and proton pump inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012\u20132016)","volume":"17","author":"Bundhun","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"10.1016\/j.bulcan.2025.04.014_bib0780","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450\u00a0activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0785","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1067\/mcp.2001.115723","article-title":"Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs","volume":"69","author":"Penning-van Beest","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.bulcan.2025.04.014_bib0790","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","article-title":"Voriconazole potentiates warfarin-induced prothrombin time prolongation","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.014_bib0795","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.2008.150","article-title":"Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding","volume":"84","author":"Schelleman","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0800","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.tru.2023.100152","article-title":"Use of direct oral anticoagulants in hematologic malignancies","volume":"13","author":"Leviatan","year":"2023","journal-title":"Thrombosis Update"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.014_bib0805","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hon.2770","article-title":"Direct oral anticoagulants in patients with hematologic malignancies","volume":"38","author":"Serrao","year":"2020","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.014_bib0675","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41409-022-01901-5","article-title":"Impact of standard-dose dipeptidyl peptidase-4\u00a0inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"58","author":"Kimura","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0680","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2027372","article-title":"Dipeptidyl peptidase 4\u00a0inhibition for prophylaxis of acute graft-versus-host disease","volume":"384","author":"Farag","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0685","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. S\u00e9maglutide (OZEMPIC\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65766192 (acc\u00e8s le 20\/09\/2024)."},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.014_bib0810","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13181-019-00755-6","article-title":"Do patients die with or from metformin-associated lactic acidosis (MALA)? Systematic review and meta-analysis of pH and lactate as predictors of mortality in MALA","volume":"16","author":"Blumenberg","year":"2020","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0815","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Sitagliptine (JANUVIA\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=60595727 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0820","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. R\u00e9paglinide (NOVONORM\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=63576333 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0825","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Glibenclamide (DAONIL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=64823509 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0830","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Dapagliflozine (FORXIGA\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=67456363 (acc\u00e8s le 20\/09\/2024)."},{"issue":"7","key":"10.1016\/j.bulcan.2025.04.014_bib0835","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.bbmt.2019.03.001","article-title":"Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan\/cyclophosphamide conditioning","volume":"25","author":"McCune","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0840","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Carbamaz\u00e9pine (TEGRETOL\u00ae) - https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=61009918.(acc\u00e8s le 20\/09\/2024)."},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0850","doi-asserted-by":"crossref","first-page":"e0280574","DOI":"10.1371\/journal.pone.0280574","article-title":"Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction","volume":"18","author":"Al-Enezi","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bulcan.2025.04.014_bib0845","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12185-019-02637-7","article-title":"Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation","volume":"109","author":"Nakashima","year":"2019","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib0855","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0018578719831974","article-title":"Valproate interaction with carbapenems: review and recommendations","volume":"55","author":"Al-Quteimat","year":"2020","journal-title":"Hosp Pharm"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib0860","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/phar.2667","article-title":"Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"42","author":"Sivakumar","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.014_bib0865","doi-asserted-by":"crossref","first-page":"e14026","DOI":"10.1111\/petr.14026","article-title":"Comparison of levetiracetam versus phenytoin\/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution","volume":"25","author":"Hughes","year":"2021","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0870","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpn.2014.10.004","article-title":"Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation","volume":"19","author":"Peyrl","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib0875","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/FTD.0000000000000938","article-title":"Decreased systemic busulfan exposure after oral dosing with concomitant levetiracetam compared with phenytoin","volume":"44","author":"Artul","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0880","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Amitryptiline (LAROXYL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65892928 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0885","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Escitalopram (SEROPLEX\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=67219535 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0890","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Fluox\u00e9tine (PROZAC\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=61885224 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0895","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Parox\u00e9tine (DEROXAT\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-ublique.medicaments.gouv.fr\/extrait.php?specid=60160707 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0900","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Sertraline (ZOLOFT\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=60155788 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0905","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Mirtazapine (NORSET\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65124914 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0910","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Dulox\u00e9tine (CYMBALTA\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66852477 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0915","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Venlafaxine (EFFEXOR\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66430942 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0920","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Mians\u00e9rine Arrow\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=62667488 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0925","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Vortiox\u00e9tine (BRINTELLIX\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=68562572 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0930","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Qu\u00e9tiapine (XEROQUEL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66429235 (acc\u00e8s le 20\/09\/2024)."},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0935","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.bmt.1705187","article-title":"Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient","volume":"37","author":"Walter","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.014_bib0940","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/ejh.13285","article-title":"Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: a systematic review of the literature","volume":"103","author":"Grainger","year":"2019","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.04.014_bib0945","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/pon.5782","article-title":"Successful continuation of clozapine treatment during hematopoietic stem cell transplantation: a step toward health equity in the oncologic care of people with severe mental illness","volume":"30","author":"Wright","year":"2021","journal-title":"Psychooncology"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0950","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Olanzapine (ZYPREXA\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=60841335 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0955","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Risp\u00e9ridone (RISPERDAL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=63605525 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0960","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Aripiprazole (ABILIFY\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65198099 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0965","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Lithium (TERALITHE\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=62124478 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0970","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Sulfam\u00e9thoxazole\/trim\u00e9thoprime (BACTRIM\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65181349 (acc\u00e8s le 20\/09\/2024)."},{"issue":"12","key":"10.1016\/j.bulcan.2025.04.014_bib0975","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S1473-3099(22)00227-4","article-title":"Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia","volume":"22","author":"Bergeron","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"618S","key":"10.1016\/j.bulcan.2025.04.014_bib0980","first-page":"23","article-title":"Les macrolides et apparent\u00e9s","volume":"61","author":"Buxeraud","year":"2022","journal-title":"Actual Pharm"},{"key":"10.1016\/j.bulcan.2025.04.014_bib0985","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Doxycycline arrow\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=67164569&typedoc=R#RcpPropPharmacocinetiques (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0990","article-title":"Allogreffe de CSH chez des patients VIH+","author":"Ceballos","year":"2024","journal-title":"state of the art. Bull Canc."},{"key":"10.1016\/j.bulcan.2025.04.014_bib0995","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Fluconazole\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66490708 (acc\u00e8s le 20\/09\/2024)."},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib1000","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0090-9556(24)14920-3","article-title":"The effect of fluconazole on cyclophosphamide metabolism in children","volume":"27","author":"Yule","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bulcan.2025.04.014_bib1005","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Voriconazole (VFEND\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66490708 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib1010","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Isavuconazole (CRESEMBA\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=69181040 (acc\u00e8s le 20\/09\/2024)."},{"key":"10.1016\/j.bulcan.2025.04.014_bib1015","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Posaconazole (NOXAFIL\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=69380042 (acc\u00e8s le 20\/09\/2024)."},{"issue":"6","key":"10.1016\/j.bulcan.2025.04.014_bib1020","first-page":"609","article-title":"Managing drug interactions in cancer therapy: a guide for the advanced practitioner","volume":"8","author":"Campen","year":"2017","journal-title":"J Adv Pract Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.014_bib1025","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.04.014_bib1030","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. Amphot\u00e9ricine B liposomale (AMBISOME\u00ae)\u00a0\u2013\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=65964911 (acc\u00e8s le 20\/09\/2024)."},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib1035","first-page":"1","article-title":"Toxicit\u00e9 des inhibiteurs de la pompe \u00e0 protons","volume":"38","author":"Macaigne","year":"2021","journal-title":"EMC"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.014_bib0520","doi-asserted-by":"crossref","first-page":"100880","DOI":"10.1016\/j.esmoop.2023.100880","article-title":"Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure","volume":"8","author":"Raoul","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.014_bib0690","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/metabo11030173","article-title":"Does DDI-predictor help pharmacists to detect drug-drug interactions and resolve medication issues more effectively?","volume":"11","author":"Moreau","year":"2021","journal-title":"Metabolites"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:03:05Z","timestamp":1779282185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125003297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0007455125003297"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.04.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticipation des probl\u00e8mes pharmacoth\u00e9rapeutiques en amont de l\u2019allogreffe (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}